News

Interlynk Inc. Selected to Support FDA Cybersecurity Compliance for a Leading Global Medical Products Company

Interlynk will provide BIOTRONIK with SBOM generation, vulnerability reporting and open-source risk assessment across its products that save and improve…

1 year ago

Inogen Announces Second Quarter 2024 Financial Results

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting,…

1 year ago

Establishment Labs Reports Second Quarter 2024 Financial Results

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,…

1 year ago

Personalized Disease Specific Patient Support, Care Coordination, and Virtual Care Delivery Tech Platform Focused on the Less Fortunate

HOUSTON, Aug. 6, 2024 /PRNewswire/ -- Founded in January 2022 Medical Resource Group DBA MRG Health Inc – Smart Care 360…

1 year ago

Cryoport Reports Second Quarter 2024 Financial Results

Revenue improved sequentially across all businessesCommercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially A record total…

1 year ago

eHealth, Inc. Announces 2025 CEO Succession Plan

Fran Soistman to Retire as CEO in early 2025, Will Remain on Board of Directors eHealth Board Commences Search for…

1 year ago

Cryoport Announces $200 Million Repurchase Program and the Repurchase of $160 Million of Convertible Senior Notes

$200 million repurchase program authorized to repurchase common stock and/or convertible notesRepurchasing approximately $160 million of 0.75% Senior Notes due…

1 year ago

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2024

Core Illumina revenue of $1.09 billion for Q2 2024, down 6% from Q2 2023 (down 6% on a constant currency…

1 year ago

Smart Data Solutions Announces New Chief Commercial Officer

EAGAN, Minn., Aug. 6, 2024 /PRNewswire/ -- Smart Data Solutions, a leading healthcare process automation company, is pleased to announce…

1 year ago

Nammi Therapeutics, Inc. Completes Series B Round with Investment from MMRF’s Myeloma Investment Fund; Advances Clinical Development of Lead Program, QXL138AM

LOS ANGELES, Aug. 6, 2024 /PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi) announces a $1M investment commitment by the Myeloma Investment…

1 year ago